MBXHealthcare · BiotechnologyThe 11 Wall Street analysts covering MBX Biosciences, Inc. hold a median 12-month price target of $88 — +80.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 13 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores MBX Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (93): The shares have been drifting up relative to others.
Volatility (17): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MBX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +80.3% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | Stifel | Maintains | Buy | $70 → $84 |
| 2 Oct 2026 | Guggenheim | Maintains | Buy | — |
| 2 Oct 2026 | Guggenheim | Maintains | Buy | $88 → $150 |
| 21 Aug 2026 | JP Morgan | Reinstates | Overweight | $88 |
| 10 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 10 Aug 2026 | Truist Securities | Maintains | Buy | $70 → $88 |
| 29 July 2026 | Mizuho | Maintains | Outperform | $57 → $91 |
| 29 July 2026 | Mizuho | Maintains | Outperform | — |
| 12 May 2026 | Barclays | Maintains | Overweight | — |
| 12 May 2026 | Barclays | Maintains | Overweight | $66 → $70 |
| 12 May 2026 | Citizens | Maintains | Market Outperform | $76 → $86 |
| 12 May 2026 | Citizens | Maintains | Market Outperform | — |
| 11 May 2026 | Truist Securities | Maintains | Buy | — |
| 11 May 2026 | Truist Securities | Maintains | Buy | $50 → $70 |
| 28 Jan 2026 | Barclays | Initiates | Overweight | — |
| 16 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 7 Jan 2026 | UBS | Initiates | Buy | — |
| 19 Dec 2025 | Stifel | Maintains | Buy | — |
| 4 Dec 2025 | Goldman Sachs | Initiates | Sell | — |
| 10 Nov 2025 | Guggenheim | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, MBX Biosciences, Inc. returned +261.1% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 67% of US stocks
Cheaper than 16% of US stocks
Cheaper than 89% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 26% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MBX Biosciences, Inc. has a market value of $2.4B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$104.3M.
Diluted earnings per share, trailing twelve months: $−2.40.
Free cash flow in the twelve months to 30 June 2026: −$85.2M.
Trailing P/E: 3.7×; forward P/E: −12.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MBX Biosciences, Inc. employs 63 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MBX Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MBX Biosciences announced that it will participate in upcoming investor conferences in November. The announcement identifies Carmel, Indiana, and Burlington, Massachusetts.
Why it matters — MBX watchers may note the planned investor-conference participation as an opportunity for the company to engage with investors.
MBX Biosciences was upgraded to Buy, driven by strong Phase 2 data for canvuparatide and a clear path toward Phase 3 success in hypoparathyroidism. The once-weekly dosing and robust efficacy position canvuparatide to challenge Yorvipath's standard-of-care status, while MBX's early-stage obesity pipeline targets a large market using monthly dosing and prodrug technology.
Why it matters — MBX watchers would care because the upgrade highlights canvuparatide's competitive potential against an established therapy and points to a promising Phase 3 outlook, alongside the obesity pipeline's large-market opportunity.
MBX Biosciences, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The item provides access to the company's conference remarks.
Why it matters — MBX watchers can review the company's latest management commentary from a major investor conference for insight into its positioning.
MBX Biosciences announced that CEO Steve Hoerter and Chief Medical Officer Sam Azoulay will present at and participate in several upcoming investor conferences. The company is a clinical-stage biopharmaceutical firm developing precision peptide therapies for endocrine and metabolic disorders.
Why it matters — This provides MBX watchers with opportunities to hear directly from leadership about the company's pipeline and strategy at investor events.
MBX Biosciences announced the appointment of Jeff Held as Chief Legal Officer, based in Carmel, Indiana and Burlington, Massachusetts. The news was distributed via GlobeNewsWire.
Why it matters — MBX watchers may view the addition of a new chief legal officer as a leadership strengthening move for the company's corporate and legal affairs.
The 11 Wall Street analysts covering MBX Biosciences, Inc. have a median 12-month price target of $88, with estimates ranging from $80 to $150. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering MBX Biosciences, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MBX Biosciences, Inc. 36 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Oct 2026, MBX Biosciences, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +80.3% from the last close, and Ticker Nerd's factor model ranks MBX Biosciences, Inc. 36 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MBX Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $150 over the next 12 months.
MBX Biosciences, Inc. returned +261.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders.
The most recent item we track (GlobeNewsWire, 13 Oct 2026): "MBX Biosciences to Participate in Upcoming November Investor Conferences". MBX Biosciences announced that it will participate in upcoming investor conferences in November. The announcement identifies Carmel, Indiana, and Burlington, Massachusetts.
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. MBX Biosciences is advancing investigational programs built around its proprietary peptide platform to address conditions such as chronic hypoparathyroidism, post-bariatric hypoglycemia, and obesity. Its pipeline includes canvuparatide, a parathyroid hormone replacement candidate, as well as additional peptide-based assets in clinical and preclinical development. The company’s work centers on designing long-acting therapies intended to improve treatment convenience and expand options in specialty endocrine care. Based in Carmel, Indiana, MBX Biosciences operates in the biotechnology and specialty therapeutics market, where it contributes to the development of targeted medicines for diseases with significant unmet medical needs.
CEO Mr. Steven L. Hoerter · 63 employees · United States · https://mbxbio.com
